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Learning objectives
 ► Understand the pathophysiology of myocardial 
fibrosis.
 ► Understand the core concepts of cardiovascular 
MRI for myocardial fibrosis.
 ► Understand the clinical implications of 
myocardial fibrosis imaging in common 
myocardial diseases.
InTroduCTIon
The current era has seen major advances in myocar-
dial imaging. We are now able to assess cardiac 
anatomy, function, tissue composition and disease 
activity across a wide range of disease states. 
Recently, there has been major interest in imaging 
myocardial fibrosis, predominantly with cardio-
vascular magnetic resonance (CMR). Fibrosis 
represents a common response to injury in most 
cardiomyopathies, but the distribution and pattern 
of fibrosis differ between pathologies, underscoring 
its potential role as a diagnostic marker. Further-
more, fibrosis is closely associated with impaired left 
ventricular function, as well as cardiac arrhythmias; 
as such, fibrosis imaging also provides powerful 
prognostic information.
In this review, we discuss the pathophysiology of 
myocardial fibrosis, review the applications of CMR 
in the non-invasive detection of myocardial fibrosis 
and provide an overview of common pathologies 
in which fibrosis imaging may be of clinical utility.
PaTHoPHysIoLogy
Our understanding of myocardial function and 
disease is largely focused on cardiomyocytes. 
However, the majority of cardiac cells in the adult 
mammalian heart are non-myocytes. Cardiac fibro-
blasts are one such cell type that play a crucial role 
in myocardial disease and healing. These cells are 
responsible for the production and deposition of 
extracellular matrix proteins—type 1 collagen being 
the prototype—which serve as a scaffold for other 
cellular components and are integral to the struc-
tural integrity and function of the myocardium. 
Fibroblasts respond to cytokines and neurohormal 
factors, differentiating into activated fibroblasts and 
smooth muscle-like myofibroblasts that are crit-
ical in the healing response of diseased or injured 
myocardium. These cells exert their effects on 
the extracellular matrix via regulation of matrix 
metalloproteinases and fibronectin. Although the 
primary response to myocardial injury—wound 
healing, reparative scar formation and remod-
elling—is important in limiting tissue damage, 
chronic changes become maladaptive, ultimately 
impairing cardiac function.
Myocardial fibrosis is a common final pathway 
in chronic myocardial disease and is the structural 
correlate of heart failure. It has traditionally been 
divided into interstitial fibrosis and replacement 
fibrosis, although more recent histology/CMR 
data have suggested considerable overlap between 
these two states.1 Diffuse interstitial fibrosis occurs 
earlier in the course of disease and represents 
collagen synthesis and deposition by differentiated 
myofibroblasts in response to a variety of stimuli. 
Importantly, reactive interstitial fibrosis is revers-
ible. A subgroup of interstitial fibrosis encapsulates 
infiltrative pathologies that deposit proteins in the 
interstitium (eg, cardiac amyloidosis). Replacement 
fibrosis represents collagen deposition that occurs 
following myocyte apoptosis or necrosis. Replace-
ment fibrosis is irreversible and is of prognostic 
relevance across a broad spectrum of myocardial 
diseases. The ability to detect and quantify fibrosis 
non-invasively—rather than relying on biop-
sies, which are limited by sampling error and the 
inability to assess the entire myocardium—is there-
fore of major clinical interest.
ImagIng TECHnIquEs
A non-invasive technique to assess myocardial 
fibrosis requires excellent temporal and spatial 
resolution in addition to the ability to characterise 
soft tissue. CMR is therefore the imaging modality 
of choice. Although CT has also been studied,2 it is 
inferior to CMR for soft-tissue characterisation. We 
will focus on the most common CMR techniques 
for fibrosis imaging—late gadolinium enhancement 
(LGE) and T1 mapping.
Cmr: replacement fibrosis
The detection and quantification of replacement 
fibrosis using CMR is an established technique and 
has a larger evidence base than techniques which 
assess diffuse interstitial fibrosis. It requires the use 
of gadolinium-based contrast agents (GBCAs) which 
shorten the T1 of tissues in which they accumulate, 
providing a high-intensity signal on T1-weighted 
imaging. These large molecule agents distribute at 
different rates into healthy and diseased myocar-
dium, partitioning into extracellular space and thus 
washing out of regions of focal replacement fibrosis 
at a slower rate than healthy tissue. The contrast 
in signal provides a visual difference between 
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Table 1 Typical CMR fibrosis findings in common pathologies
LgE T1 mapping
Ischaemic cardiomyopathy  ► Subendocardial involvement
 ► Variable transmural extension
 ► Coronary artery territory distribution
 ► Quantitative native T1 may perform similarly to LGE for detecting chronic 
infarction
 ► ECV and native T1 in non-infarcted myocardium appear to be elevated
DCM  ► Non-ischaemic distribution, often mid-wall/subepicardial  ► ECV and native T1 may be elevated
Aortic stenosis  ► Typically non-ischaemic mid-wall distribution
 ► May have subendocardial involvement
 ► ECV, iECV and native T1 may be elevated
 ► Post-AVR findings vary depending on relative regression of cellular and 
extracellular constituents of myocardium.
Hypertrophic cardiomyopathy  ► Patchy non-ischaemic distribution in regions of focal wall thickening, or 
at the right ventricular insertion points in the septum
 ► ECV and native T1 may be elevated, even in patients without LGE
Myocarditis  ► At least one focal lesion in non-ischaemic distribution; often 
inferolateral and subepicardial
 ► Used in conjunction with T2 mapping and early gadolinium 
enhancement for oedema and hyperaemia
 ► Native T1 may offer greater diagnostic accuracy in myocarditis than LGE and 
traditional Lake Louise criteria
 ► Not specific for acute vs chronic myocarditis
Cardiac amyloidosis  ► Diffuse myocardial uptake
 ► Difficult to null images —black blood pool rather than white
 ► ECV and native T1 elevated and may quantify disease burden
Cardiac sarcoidosis  ► Non-specific appearances
 ► Multi-focal, non-ischaemic distribution is suggestive
 ► Native T1 may discriminate sarcoidosis from healthy controls
 ► Regresses with anti-inflammatory therapy
AVR, aortic valve replacement; CMR, cardiovascular magnetic resonance; DCM, dilated cardiomyopathy; iECV, indexed extracellular volume; LGE, late gadolinium enhancement.
Figure 1 T1 mapping in cardiovascular magnetic resonance modified Look-Locker inversion recovery sequence. A sequence of three inversion 
recovery experiments are performed with images acquired and ordered according to inversion times. Signals are then used to plot a T1 recovery curve. 
The T1 value is the time when T1 recovery is 63% complete. T1 values are then used to create a voxel map. Adapted from Everett et al.58
areas of replacement fibrosis (white) and healthy 
myocardium (black), although it is insensitive for 
detecting reactive interstitial fibrosis due to the 
diffuse nature of this type of fibrosis. Importantly, 
manual selection of the inversion time to null the 
myocardium at the time of acquisition is required 
to achieve this visual contrast, introducing some 
subjectivity. Late gadolinium enhancement (>7 min 
after injection, LGE) is the standard parameter and 
is usually presented as either a dichotomous finding 
or a percentage of myocardial volume. Both the 
presence and volume of LGE are almost universally 
associated with a poorer prognosis in myocardial 
disease. Different patterns of LGE are associated 
with different disease states (table 1).
Cmr: interstitial fibrosis
T1 mapping is the cornerstone of interstitial fibrosis 
imaging with CMR. There are several different 
approaches, including native T1, extracellular 
volume fraction (ECV%) and indexed extracellular 
volume (iECV). These techniques are comprehen-
sively reviewed elsewhere3 and guidelines for their 
use have been published.4 Briefly, T1 mapping inter-
rogates tissue recovery from longitudinal magneti-
sation (relaxation) following saturation (90 degrees) 
or inversion (180 degrees) pre-pulses (figure 1). 
Various protocols are used. Images are acquired at 
several timepoints during recovery, with T1 times 
encoded as signal intensities within each voxel. 
Clinical interpretation is facilitated by applying 
colour look-up tables for visual assessment; various 
vendors may supply automated colour maps.
Native T1 values (milliseconds) are measured 
without GBCAs and reflect the combined intra-
cellular and extracellular compartments. Values 
increase with a greater burden of fibrosis and are 
usually measured on a per-segment basis. In contrast, 
ECV% (percentage) and iECV (mL or mL/m2) use 
GBCAs to target the extracellular space. ECV% 
represents the extracellular matrix as a proportion 
of total left ventricular myocardial volume, whereas 
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Figure 2 Ischaemic cardiomyopathy extensive anteroseptal myocardial infarction. Two-chamber (left) and short-axis (right) views demonstrate 
transmural late gadolinium enhancement in the left anterior descending artery territory with associated wall thinning, suggesting no viability.
iECV adjusts for left ventricular myocardial volume 
(ECV%×left ventricular myocardial volume) and 
offers a measure of absolute matrix volume.5 6
A barrier to the widespread adoption of T1 mapping 
has been standardisation between vendors and 
sequences and unclear thresholds for normal values. 
Recently, extensive research has been conducted as 
part of the International T1 Multicentre Outcome 
CMR Study (NCT02407197, NCT03749343) to 
develop and validate cross-vendor sequences that 
are transferable, reproducible and easy to acquire. 
Consequently, T1 mapping is now at the forefront of 
myocardial imaging research.
Given the distinct differences between reactive 
interstitial fibrosis and replacement fibrosis, the 
combination of CMR T1 mapping and LGE offers a 
comprehensive assessment of myocardial disease that 
is currently unmatched by any other imaging modality.
FIbrosIs ImagIng In myoCardIaL dIsEasEs
Imaging of myocardial fibrosis using CMR has 
been studied in a variety of cardiovascular condi-
tions for both diagnosis and prognosis. Guide-
lines endorsing standardised image acquisition 
and analysis have been published.7 We will discuss 
some of the more common clinical applications of 
fibrosis imaging.
Ischaemic cardiomyopathy and myocardial 
infarction
Myocardial infarction is the prototypical model 
of myocyte necrosis, apoptosis and collagen depo-
sition with the formation of scar (replacement 
fibrosis). LGE in myocardial infarction occurs in 
epicardial coronary artery territories and may be 
subendocardial or transmural, often accompanied 
by regional wall motion abnormalities or wall thin-
ning (figure 2). The most common clinical role 
for myocardial fibrosis imaging in ischaemic heart 
disease is to establish viability.8 Although transmu-
rality of LGE is a continuum, wall motion recovery 
rarely occurs if >75%. The presence and quantity 
of LGE is a strong independent predictor of adverse 
outcomes and mortality.9–11
In addition to the prognostic implications of LGE, 
it is important to appreciate the diagnostic utility 
of CMR in suspected myocardial infarction. In the 
current era of high-sensitivity cardiac troponin, 
there is often diagnostic uncertainty in patients 
with chest pain, a normal ECG and a small eleva-
tion in troponin concentration, particularly when 
obstructive coronary artery disease is not observed 
on angiography. In these cases of myocardial injury 
with non-obstructed coronary arteries, CMR may 
offer a diagnosis based on the pattern of injury and 
myocardial dysfunction.12 Furthermore, in patients 
with suspected non-ST elevation myocardial infarc-
tion (NSTEMI) who proceed to coronary angiog-
raphy, the culprit lesion if often unclear. A recent 
prospective study in 114 patients presenting with 
their first NSTEMI elegantly demonstrated the 
ability of LGE on CMR to alter either the diagnosis 
and/or the designated culprit lesion in nearly half 
the cohort.13
T1 mapping has also been investigated. Studies 
in patients with myocardial infarction have demon-
strated the ability of T1 mapping to quantify 
infarct size and differentiate reversible and irrevers-
ible myocardial injury,14 15 while recent research 
in stable coronary artery disease has shown the 
prognostic importance of native T1 and ECV in 
non-infarcted myocardium.16 17 However, further 
studies are now required to determine whether T1 
mapping has clinical utility as a dynamic biomarker 
to guide therapies.
dilated cardiomyopathy
Dilated cardiomyopathy (DCM) is a major cause 
of cardiovascular morbidity and mortality, with 
heterogeneous mechanisms governing ventricular 
dysfunction, arrhythmias and sudden cardiac death. 
CMR can aid characterisation of the underlying 
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Figure 4 Aortic stenosis myocardial fibrosis in aortic stenosis. There is non-ischaemic late gadolinium enhancement in the basal inferolateral and 
inferior wall, where the subendocardium is spared (red arrow).
Figure 3 Non-ischaemic dilated cardiomyopathy. Four-chamber (left) and short-axis (right) views demonstrate anteroseptal and inferoseptal late 
gadolinium enhancement in a typical non-ischaemic (mid-wall) distribution. Note sparing of the subendocardium.
pathology (figure 3). Around a third of patients 
with DCM demonstrate a non-ischaemic pattern 
of LGE (mid-wall or subepicardial), which is again 
a predictor of adverse outcomes, including heart 
failure, ventricular arrhythmias, sudden cardiac 
death and all-cause mortality.11 18 19 T1 mapping 
has also been investigated in DCM, providing 
complementary information to LGE. T1 mapping 
may discriminate healthy from diseased myocar-
dium, correlating with histology.20 21 Most recently, 
investigators have shown T1 mapping to be a strong 
predictor of all-cause mortality and heart failure, 
death or hospitalisation, independent of standard 
measures of risk such as ejection fraction and func-
tional status.17 22
These early data highlight the need for more 
prospective studies of myocardial fibrosis imaging as a 
risk stratifying tool in DCM. In light of recent data,23 
there is currently equivocation regarding the optimal 
use of implantable cardioverter-defibrillators for 
primary prevention in DCM. Indeed, many clinicians 
opt not to proceed with this intervention in patients 
who meet current guideline-recommended criteria.24 
Studies such as CMR GUIDE (NCT01918215), a 
randomised controlled trial allocating patients with 
mild–moderate left ventricular systolic dysfunction to 
primary prevention implantable cardioverter-defibril-
lator or loop recorder based on LGE,25 are keenly 
awaited.
aortic stenosis
Aortic stenosis is the best-studied valvular heart 
disease with regards to myocardial fibrosis imaging. 
In recent years, there has been a paradigm shift in the 
assessment and risk stratification of aortic stenosis, 
with more focus on the myocardium. Current Euro-
pean Society of Cardiology guidelines recommend 
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Figure 5 Hypertrophic cardiomyopathy examples of hypertrophic cardiomyopathy with typical septal hypertrophy (right) and an apical variant (left). 
Patchy non-infarct late gadolinium enhancement is seen within the regions of wall thickening.
aortic valve intervention in symptomatic aortic 
stenosis, reflecting the standard clinical practice 
in place for many years.26 However, there is major 
uncertainty regarding the timing of intervention in 
asymptomatic patients. Guidelines suggest a variety 
of factors that may influence this decision—for 
example, an ejection fraction <50%, elevated brain 
natriuretic peptide levels or a peak aortic velocity 
>5.5 m/s—but these are weak recommendations 
supported by level C evidence.
As such, there is a clinical need for more sophis-
ticated risk stratification. CMR fibrosis imaging has 
the potential to fill this role.27 Myocardial fibrosis 
in aortic stenosis reflects chronically elevated left 
ventricular afterload which results in a number 
of pathological changes including cellular hyper-
trophy, expansion of the extracellular matrix 
and ischaemia due to supply–demand mismatch 
(figure 4). Multiple cohorts have demonstrated the 
presence of both infarct and non-infarct LGE to 
be independently associated with mortality.5 28–31 
Furthermore, once established, replacement fibrosis 
progresses rapidly and does not regress after aortic 
valve replacement.6 32 This is particularly important 
as there appears to be a “dose-dependent” asso-
ciation between LGE and cardiovascular as well 
as all-cause mortality.31 These observations have 
formed the basis for current prospective research, 
including the EVOLVED trial (NCT03094143), 
which is the first randomised controlled trial to 
use LGE as a trigger for aortic valve replacement in 
asymptomatic severe aortic stenosis.33
The natural progression of myocardial fibrosis 
imaging in aortic stenosis is the investigation 
of diffuse interstitial fibrosis—that is, detecting 
myocardial disease at an early, reversible stage. 
This is relevant as interstitial fibrosis can regress 
after aortic valve replacement.6 A number of obser-
vational studies have demonstrated correlations 
between diffuse fibrosis parameters (native T1, 
ECV% and iECV) and histology; however, data 
investigating the associations between these markers 
and clinical outcomes are limited at present.5 34 35
Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy is the most common 
genetic cardiomyopathy. It is characterised by 
inappropriate regional wall thickening (figure 5), 
although there is significant phenotypic heteroge-
neity. Hypertrophic cardiomyopathy remains the 
leading cause of sudden cardiac death in young 
patients, although most patients have few clinical 
symptoms and overall event rates are low. As such, 
there is a major need for tools to improve patient 
risk stratification. Current risk stratification is 
imperfect, with strategies based on observational 
data.36
In addition to its diagnostic role, CMR has been 
proposed as a means of better identifying patients 
at high risk of sudden cardiac death. Although indi-
vidual studies have been limited by small numbers, 
meta-analyses have demonstrated that both the 
presence and quantity of LGE are independently 
associated with all-cause and cardiac death.37 
Importantly, the prevalence of LGE on CMR is 
around 50%–70%, ranging from patchy non-in-
farct distribution within hypertrophied segments 
to full-thickness enhancement with wall thinning 
in end-stage disease.36 Consequently, the positive 
predictive value of LGE for events remains low. 
However, the risk of sudden cardiac death appears 
to increase with increasing LGE burden (eg, HR 
1.86 (95% CI 1.21 to 2.86) for 20% LGE; HR 3.45 
(95% CI 1.46 to 8.16) for 40% LGE), suggesting 
that a minimum threshold for LGE volume may be 
of more clinical use. Further prospective studies are 
required to address this issue. As such, current 2014 
European Society of Cardiology guidelines provide 
a class IIa (level of evidence B) recommendation for 
the assessment of myocardial fibrosis with CMR in 
hypertrophic cardiomyopathy, but do not integrate 
CMR into clinical risk stratification models.36
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Figure 7 Cardiac amyloidosis and sarcoidosis. Left: cardiac amyloidosis. Note the black blood pool and diffuse late gadolinium enhancement within 
the abnormal myocardium. Right: cardiac sarcoidosis. The distribution of late gadolinium enhancement in cardiac sarcoidosis is variable. Here, there is 
a large burden of confluent enhancement in the inferior and inferolateral wall.
Figure 6 Myocarditis. Three-chamber (left) and short-axis (right) examples of patchy, non-infarct, mid-wall late gadolinium enhancement in the 
anterolateral and inferolateral walls of a patient with chronic myocarditis (3 months after the onset of symptoms). Note that these findings are non-
specific.
T1 mapping has been investigated in hypertro-
phic cardiomyopathy in small studies. Native T1 
and ECV are able to differentiate healthy from 
diseased myocardium21 and may discriminate 
between hypertrophic cardiomyopathy and other 
conditions such as hypertensive heart disease.38 
Beyond these preliminary data, however, the role 
of T1 mapping in hypertrophic cardiomyopathy 
requires further elucidation.
myocarditis
Myocarditis is an inflammatory disease of the 
myocardium which can be acute, subacute or 
chronic and is caused by a variety of aetiologies—
most commonly viral or idiopathic. The true inci-
dence is difficult to ascertain but there appears to be 
a trend of increasing hospitalisation in recent years, 
in part due to high-sensitivity cardiac troponin 
assays and access to CMR.39 Myocarditis may be 
present in up to 12% of young adults presenting 
with sudden death and can lead to other diseases 
such as DCM.40 Adverse events in patients with 
confirmed myocarditis are lower in contemporary 
series than historic cohorts, but remain signifi-
cant, particularly in patients with a complicated 
presentation (cardiac mortality and transplantation 
11.3% at 1 year in patients with ejection fraction 
<50%, sustained ventricular arrhythmia or low 
output state).41 The initial inflammatory response, 
myocyte injury and tissue oedema may be followed 
by myocyte necrosis and the development of scar. 
Consequently, CMR is now an established imaging 
modality for the diagnosis of myocarditis. CMR 
uses T1-weighted and T2-weighted imaging, early 
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gadolinium enhancement and LGE to detect hyper-
aemia, oedema and non-infarct replacement fibrosis, 
and diagnostic criteria (Lake Louise criteria) have 
been proposed based on observational data and 
expert consensus.40 42 LGE is seen in the majority 
of patients and is commonly distributed in the 
subepicardial inferior and lateral walls as well as the 
septum (figure 6).43 44 More recently, T1 mapping 
has been explored, with both native T1 and ECV 
demonstrating superior correlation with endomyo-
cardial biopsy compared with Lake Louise criteria 
for the diagnosis of acute myocarditis (defined in 
this study as ≤14 days; area under the curve 0.77, 
0.75 and 0.52, respectively).45 This highlights the 
ability of T1 mapping to detect increased extracel-
lular volume due to oedema and reactive fibrosis 
during the early inflammatory response. Impor-
tantly, however, the diagnostic value of T1 mapping 
diminished in patients with symptoms >14 days.
The prognostic significance of CMR findings are 
restricted to LGE at present. The presence of non-in-
farct LGE is a powerful independent predictor of 
adverse events,46 even in patients without evidence 
of heart failure or left ventricular systolic dysfunc-
tion at presentation.44
Infiltrative diseases
The most commonly encountered infiltrative 
cardiomyopathies are cardiac amyloidosis and 
sarcoidosis, which will be discussed here. Others 
include haemochromatosis and Fabry disease, both 
of which have characteristic findings on LGE, T1 
and T2* mapping. These disease processes differ 
slightly from other pathologies as their hallmark is 
deposition of abnormal proteins within the inter-
stitial space, rather than reactive inflammatory 
fibrosis and myocyte necrosis seen in previously 
discussed diseases. Research into these diseases is 
largely limited to observational studies.
The hallmark of amyloidosis is extracellular depo-
sition of fibrils, comprising low molecular weight 
subunits of serum proteins. The most common types 
of primary amyloidosis are light-chain and trans-
thyretin (senile) cardiac amyloidosis. The former is a 
plasma cell dyscrasia which leads to monoclonal light-
chain deposition, with cardiac involvement occurring 
in up to 50% of cases. This type of amyloidosis is 
responsible for the majority of systemic amyloidosis. 
The latter results in deposition of misfolded trans-
thyretin and may be present in up to 10%–15% of 
older patients with heart failure. CMR offers an ideal 
modality for the diagnosis and assessment of cardiac 
amyloidosis given its ability to interrogate the cardiac 
interstitium. The presence of LGE is nearly universal 
in patients with confirmed cardiac amyloidosis.47 
The typical distribution is global subendocardial or 
transmural LGE (figure 7), representing a gradient in 
burden of disease as assessed by ECV%.48 An addi-
tional typical finding in cardiac amyloid is difficulty 
in determining the optimal inversion time to null the 
myocardium. In other conditions, the blood pool is 
typically bright due to high concentrations of gado-
linium; the null point of the blood pool is reached 
before the myocardium. In cardiac amyloidosis, the 
null point of the myocardium is reached before the 
blood pool due to high myocardial uptake and fast 
blood washout, resulting in a dark blood pool.49 
CMR LGE in a characteristic pattern has been 
shown to have a high sensitivity and specificity for 
cardiac amyloidosis as well as prognostic power for 
mortality.47–50 ECV% and native T1 may also quan-
tify amyloid burden and are independently associated 
with mortality.51 52 The incremental information 
provided by these CMR techniques is particularly 
pertinent given the recent successes of targeted thera-
pies for transthyretin amyloid cardiomyopathy.
Sarcoidosis is a multiorgan, chronic, inflamma-
tory granulomatous disease of unknown cause. 
Cardiac involvement occurs in up to one quarter 
of patients, although more than half of these 
patients may have subclinical disease.53 Classically 
the great mimic, cardiac sarcoidosis is frequently 
difficult. CMR is the diagnostic imaging modality 
of choice. Although there is no pathognomonic 
distribution of LGE (figure 7), typical patterns 
include multifocal LGE in a non-infarct pattern 
(although subendocardial disease is also seen) 
and direct extension of LGE across the septum 
from both right ventricular insertion points. The 
strength of CMR for the diagnosis of cardiac 
sarcoid lies largely in its sensitivity and excellent 
negative predictive value.54 As with other disease 
processes, the presence of LGE in cardiac sarcoid-
osis is of prognostic relevance, demonstrating an 
independent association with mortality.55 While 
the evidence base is somewhat limited, CMR LGE 
imaging is recommended in the current 2014 
Heart Rhythm Society expert consensus criteria56 
to aid in the diagnosis of cardiac sarcoidosis 
and as an arbiter of risk for ventricular arrhyth-
mias—thus influencing decisions about invasive 
electrophysiology studies and primary prevention 
implantable cardioverter-defibrillators. Mean-
while, T1 and T2 mapping have been investigated 
as direct measures of inflammation, oedema and 
diffuse fibrosis, demonstrating an excellent ability 
to discriminate between patients with sarcoid-
osis and controls, outperforming current stan-
dard diagnostic criteria and additionally showing 
improvement after anti-inflammatory therapy.57
ConCLusIon
Across a breadth of pathologies, myocardial fibrosis 
represents a final common pathway of myocardial 
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disease, with the pattern and distribution of fibrosis 
differing between conditions. Irreversible replace-
ment fibrosis, represented by LGE on CMR, is 
of nearly universal prognostic relevance. Mean-
while, diffuse interstitial fibrosis imaging has been 
shown to have great potential as a dynamic, early 
and reversible marker of myocardial disease. Both 
approaches are being used increasingly in clinical 
practice as diagnostic adjuncts, but data demon-
strating that CMR improves outcomes in a cost-ef-
fective manner are lacking. Further clinical trials 
are required for this purpose, and several major 
observational and randomised controlled trials are 
currently underway.
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